Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / United Kingdom

AstraZeneca Acquires MedImmune

April 2007 | Company Finance Alert

UK-based drugmaker AstraZeneca will enter the vaccines market in strength after agreeing a US$15.2bn fee for US-based biotech MedImmune . The deal, which will significantly boost AstraZeneca's pipeline, comes after the company decided to end development for heart disease treatment AGI-1067, its fourth major failure in the space of a year.

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *


If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.

Western Europe InsightWestern Europe Channels Western Europe Countries